Please assess the completion status of the following clinical trial:

Trial Title: K-924 Phase III Confirmatory Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with hypercholesterolemia had to be age 20 years or older at written informed consent (ICF)~2. Patients who have been on a diet and / or exercise regimen more than 12 weeks before the screening~3. Those whose LDL-C (Friedewald formula) at the screening any of the following in the category classification based on Japan Atherosclerosis Society guidelines for prevention Atherosclerotic Cardiovascular Disease 2017~   * Low risk of primary prevention : LDL-C =\> 160 mg/dL~  * Medium risk of primary prevention : LDL-C =\> 140 mg/dL~  * High risk of primary prevention : LDL-C =\> 120 mg/dL~Exclusion Criteria:~1. Patients with a history of myopathy or rhabdomyolysis due to pitavastatin or ezetimibe~2. Patients with a history of hypersensitivity due to pitavastatin or ezetimibe~3. Patients with severe liver damage (Child Pugh Class B or higher) or biliary obstruction~4. Pregnant women, lactating women, women planning to become pregnant or lactating during the study period, or pregnant women who do not use specific contraceptive methods~5. Patients whose CK is 3 times or more of the upper limit of the reference value at screening~6. Patients whose AST and ALT is 2 times or more of the upper limit of the reference value at screening~7. Patients wiht type 1 diabetes or uncontrolled type 2 diabetes as defined HbA1c 8% or more at screening~8. Patients with uncontrolled hypertension as defined systolic blood pressure of 160 mmHg or more or diastolic blood pressure of 100 mmHg or more at screening~9. Patients with eGFR of less than 30 mL / min / 1.73 m² at screening or dialysis~10. Patients with heart failure class III or higher according to NYHA cardiac function classification~11. Patients with uncontrolled arrhythmia~12. Patients with uncontrolled metabolic endocrine disease~13. Patients with a history of coronary artery disease or patient with familial hypercholesterolemia~14. Patients with malignant tumors or who are judged to have a high possibility of relapse~15. Patients who have collected 200 mL or more within 4 weeks before screening, 400 mL or more of blood within 12 weeks for males or 16 weeks for females, or within 2 weeks for (Plasma component / platelet component)~16. Persons with a history of severe drug allergy (anaphylactic shock, etc.)~17. Patients who need contraindicated drugs during the study period after obtaining consent~18. Patients with TG of 400 mg / dL or more at screening~19. Patients who have LDL apheresis~20. Patients with malabsorption or history, or who have undergone gastrointestinal surgery (excluding appendectomy, hernia treatment, etc.) that may affect absorption.~21. Patients with Alcohol or drug addiction~22. Patients who participate in other clinical trials within 16 weeks prior to study drug administration and who are administered non-placebo investigational drugs, or who participate in other clinical trials concurrently with this study~23. Patients who have received K-924~24. Patients who judged to be inappropriate by the Investigator or Investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- K-924 LD (Type: EXPERIMENTAL): K-924 LD tablet once daily
- K-924 HD (Type: EXPERIMENTAL): K-924 HD tablet once daily
- Pitavastatin 2 mg (Type: ACTIVE_COMPARATOR): K-924 LD Placebo tablet once daily
- Pitavastatin 4 mg (Type: ACTIVE_COMPARATOR): K-924 HD Placebo tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete